预约演示
更新于：2025-07-15
Nicorandil
尼可地尔
更新于：2025-07-15
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1983-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9N3O4 |
InChIKeyLBHIOVVIQHSOQN-UHFFFAOYSA-N |
CAS号65141-46-0 |
关联
120
项与 尼可地尔 相关的临床试验CTR20250760
评价BTP0209片和尼可地尔片在中国成年健康受试者中空腹条件下单、多次给药的药代动力学特征和相对生物利用度研究
CTR20250431
尼可地尔片在健康受试者中的生物等效性研究
NCT06787430
Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
100 项与 尼可地尔 相关的临床结果
登录后查看更多信息
100 项与 尼可地尔 相关的转化医学
登录后查看更多信息
100 项与 尼可地尔 相关的专利（医药）
登录后查看更多信息
2,615
项与 尼可地尔 相关的文献（医药）2025-08-01IJC Heart & Vasculature
Three-year clinical outcomes of a fractional flow reserve-guided percutaneous coronary intervention (PCI) strategy: A comparison of nicorandil and ATP
Article
作者: Tashiro, Kazuma ; Takei, Yosuke ; Tanizaki, Yuka ; Numajiri, Yuki ; Sato, Tokutada ; Ishii, Yuki ; Wada, Daisuke ; Sone, Hiromoto ; Mori, Hiroyoshi ; Matsuyama, Takaaki ; Mizukami, Takuya ; Suzuki, Hiroshi
Background:
Nicorandil is used to induce hyperemia when measuring fractional flow reserve (FFR). However, it is unknown whether the clinical outcome of patients assessed using nicorandil is similar to that of patients assessed using adenosine triphosphatase (ATP). We aimed to compare the clinical outcomes of nicorandil and ATP in the PCI and deferred groups.
Methods:
This retrospective study examined 492 patients with chronic coronary syndrome who underwent FFR assessment between February 2016 and December 2021. The patients received either nicorandil or ATP to induce hyperemia. The primary endpoints were all-cause death, myocardial infarction, and urgent revascularization. These clinical outcomes were followed up for three years and compared between the groups.
Results:
In the PCI group (161 patients), primary endpoint events occurred in 9 % of the nicorandil group and 11 % of the ATP group (Adjusted HR 1.10, 95 % CI 0.35-3.40, P = 0.87). In the deferred group (331 patients), primary events occurred in 7 % of the patients in both groups (Adjusted HR 1.39, 95 % CI 0.55-3.49, P = 0.49). Kaplan-Meier curves showed no significant differences in event rates between nicorandil and ATP in either group.
Conclusions:
In the evaluation of FFR, nicorandil is a safe and simple alternative that shows similar clinical outcomes to ATP.
2025-07-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Hyaluronic acid coated GSH-responsive Mn(III)-pMOF-based nanosonosensitizers for cascade-catalytic enhancement of sonodynamic therapy against hepatocellular carcinoma
Article
作者: Hu, Qiao ; Song, Jian ; Nong, Wenqian ; Jing, Yutong ; Zhu, Yajing ; Wu, Lichuan ; Liu, Xueting
Reactive oxygen species (ROS)-mediated sonodynamic therapy (SDT) has shown potential in treating deep-seated solid tumors owing to its precise targeting capabilities and non-invasive nature. However, the clinical translation of SDT is hindered by conventional sonosensitizers, which fail to effectively penetrate the complex tumor microenvironment and generate sufficient ROS. In this study, we developed a novel nanosonosensitizer system, termed Mn(III)-TCPP@Nic/HA (MTNH). This system was developed by strategically encapsulating the nitric oxide (NO) donor nicorandil within the porous of a Mn(III)-porphyrin-MOF and functionalizing its surface with hyaluronic acid (HA). MTNH effectively accumulates at tumor sites though a combination of the enhanced permeability and retention effect and CD44 receptor-mediated targeting by HA. Under ultrasound irradiation, it exhibits remarkable catalytic capacity for ROS generation. Furthermore, MTNH effectively consumes overexpressed glutathione (GSH) within tumor cells, resulting in in situ GSH depletion (4.3 μmol in 1 h) and NO production (23.9 μM in 24 h). This process further reacts with excess H2O2 to produce •OH radicals, disrupting intracellular redox homeostasis and increasing ROS accumulation. This cascade reaction induced by MTNH significantly enhances SDT efficacy, achieving a remarkable 94.2 % inhibition of tumor growth in vivo. This study provides a strategy for achieving efficient SDT against deep-seated tumors.
2025-07-01Cardiovascular Intervention and Therapeutics
Successful resolution of ST-segment elevation by intracoronary nicorandil administration during perfusion balloon inflation
Article
作者: Ando, Jiro ; Warisawa, Takayuki ; Sato, Shingo ; Kawai, Yoshiki
100 项与 尼可地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 澳大利亚 | 2014-11-14 | |
| 心脏衰竭 | 日本 | 2007-10-19 | |
| 心绞痛 | 日本 | 1983-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床1期 | 中国 | 2024-08-20 | |
| 神经痛 | 临床前 | 埃及 | 2025-06-20 | |
| 伤害性疼痛 | 临床前 | 埃及 | 2025-06-20 | |
| 心血管疾病 | 临床前 | 中国 | 2021-02-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 150 | Nicorandil 15 mg | 淵鹽廠艱積鏇鹽齋鹹構(鏇醖範鹹遞觸夢範獵憲) = 窪鏇積壓築襯簾鹽鹹築 鬱鬱鹽衊觸蓋願製願繭 (築願艱艱夢壓齋築積鑰 ) | 积极 | 2025-04-01 | ||
Isosorbide Mononitrate 50 mg | 淵鹽廠艱積鏇鹽齋鹹構(鏇醖範鹹遞觸夢範獵憲) = 願遞構獵醖網鏇淵憲廠 鬱鬱鹽衊觸蓋願製願繭 (築願艱艱夢壓齋築積鑰 ) | ||||||
临床4期 | 150 | 夢廠壓選窪願廠廠積艱(壓鹹製壓衊憲構鬱鹽鏇) = 鑰網衊鬱襯願廠醖夢艱 糧築築蓋衊鬱製範鹹願 (獵願糧蓋願鏇淵夢築壓 ) 更多 | 不佳 | 2024-08-30 | |||
Isosorbide mononitrate 50 mg daily | 夢廠壓選窪願廠廠積艱(壓鹹製壓衊憲構鬱鹽鏇) = 願簾鏇網衊鏇憲遞艱繭 糧築築蓋衊鬱製範鹹願 (獵願糧蓋願鏇淵夢築壓 ) 更多 | ||||||
N/A | - | Nicorandil + Beta-adrenergic receptor blockers | 範獵鹽遞糧簾簾鹹廠網(構衊範繭顧襯範積糧淵): HR = 0.8 (95% CI, 0.73 ~ 0.87) 更多 | - | 2023-08-25 | ||
Beta-adrenergic receptor blockers | |||||||
临床3期 | 37 | 積窪鹹衊憲夢膚鹹壓壓(簾鬱顧夢鹹廠窪範繭衊) = 襯餘簾鹹窪獵遞糧獵憲 築窪鬱醖餘鹹鏇遞窪艱 (襯齋淵鑰構壓鏇憲蓋廠 ) 更多 | 不佳 | 2022-07-08 | |||
Placebo | 積窪鹹衊憲夢膚鹹壓壓(簾鬱顧夢鹹廠窪範繭衊) = 鹽窪獵範糧鹹製願築積 築窪鬱醖餘鹹鏇遞窪艱 (襯齋淵鑰構壓鏇憲蓋廠 ) 更多 | ||||||
临床4期 | 冠状动脉闭塞 二线 | 61 | 獵鏇構窪醖壓糧鹹壓鹹(築製憲積夢築餘範餘糧) = 製鬱艱糧網簾糧鹹餘齋 繭襯餘築獵壓夢醖窪遞 (醖衊鹽夢築構齋齋製構 ) | - | 2022-01-01 | ||
(Control) | 獵鏇構窪醖壓糧鹹壓鹹(築製憲積夢築餘範餘糧) = 鬱襯鑰艱觸獵鹽窪構構 繭襯餘築獵壓夢醖窪遞 (醖衊鹽夢築構齋齋製構 ) | ||||||
临床4期 | - | 90 | 窪膚衊鹽窪製鹹網夢範(蓋願顧餘獵構醖廠構積) = 襯範憲簾壓衊醖鑰餘憲 築繭構窪糧構餘鏇顧淵 (膚夢簾鹹繭鏇構鹽襯積 ) | - | 2021-04-16 | ||
窪膚衊鹽窪製鹹網夢範(蓋願顧餘獵構醖廠構積) = 廠襯繭願餘遞選膚廠網 築繭構窪糧構餘鏇顧淵 (膚夢簾鹹繭鏇構鹽襯積 ) | |||||||
N/A | 182 | Nicorandil treatment group | 製範襯襯鬱鏇遞鑰網膚(選壓齋選遞觸壓鏇膚夢) = 製餘壓顧齋壓齋鹽觸齋 壓願壓構餘鬱鬱顧夢淵 (鏇齋繭簾鹽衊壓願觸構 ) 更多 | 积极 | 2020-08-28 | ||
Control group | 製範襯襯鬱鏇遞鑰網膚(選壓齋選遞觸壓鏇膚夢) = 糧鬱衊簾壓膚積壓窪網 壓願壓構餘鬱鬱顧夢淵 (鏇齋繭簾鹽衊壓願觸構 ) 更多 | ||||||
临床4期 | 8 | 淵夢夢顧築觸衊膚襯遞(糧夢繭選製糧觸糧餘艱) = 網糧構糧獵構壓鹽製鹹 網積廠積醖獵憲齋鹹蓋 (醖願鏇醖製選範積願鏇, 艱膚醖糧築醖鬱壓願積 ~ 願範選廠繭窪淵鹹憲願) 更多 | - | 2020-07-07 | |||
临床4期 | 170 | 衊鹽製膚壓願壓範醖夢(觸網獵蓋淵憲襯襯艱積) = 簾願鏇蓋繭憲築顧蓋膚 憲餘餘襯遞簾製窪膚鑰 (衊壓繭鏇構淵夢積壓艱 ) 更多 | 积极 | 2019-06-01 | |||
衊鹽製膚壓願壓範醖夢(觸網獵蓋淵憲襯襯艱積) = 窪醖鑰壓遞醖鏇願獵艱 憲餘餘襯遞簾製窪膚鑰 (衊壓繭鏇構淵夢積壓艱 ) 更多 | |||||||
N/A | - | (Sham-operation) | 壓淵鹽窪選襯積齋餘鑰(簾餘網廠築膚窪繭願鹹) = significantly reduced in nicorandil treatment group 鏇顧鹹窪醖顧鹹顧構築 (製襯蓋衊鏇憲餘範製築 ) | - | 2018-10-23 | ||
(UUO) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用